BUSINESS● LOW1h ago · Oct 29, 2026, 3:01 AM
DBV expects cash runway into Q3 2027 as it advances sequential FDA reviews for VIASKIN Peanut BLAs
Seeking Alpha Tech · global
DBV anticipates having sufficient cash reserves until the third quarter of 2027 while progressing with sequential FDA reviews for its VIASKIN Peanut BLAs. This indicates the company's financial stability and regulatory progress for its product.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS18m agoMagyar Bancorp raises quarterly dividend by 12% to $0.12/shareSeeking Alpha TechBUSINESS19m agoThursday’s Economic CalendarSeeking Alpha Tech